A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 20,375 shares of RXRX stock, worth $140,180. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,375
Previous 22,292 8.6%
Holding current value
$140,180
Previous $167,000 19.76%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$5.92 - $8.6 $11,348 - $16,486
-1,917 Reduced 8.6%
20,375 $134,000
Q2 2024

Aug 12, 2024

SELL
$7.35 - $10.05 $19,271 - $26,351
-2,622 Reduced 10.52%
22,292 $167,000
Q1 2024

May 09, 2024

SELL
$9.13 - $15.52 $10,417 - $17,708
-1,141 Reduced 4.38%
24,914 $248,000
Q4 2023

Feb 08, 2024

SELL
$5.09 - $10.79 $35,360 - $74,958
-6,947 Reduced 21.05%
26,055 $256,000
Q3 2023

Nov 07, 2023

BUY
$6.59 - $15.86 $12,771 - $30,736
1,938 Added 6.24%
33,002 $252,000
Q2 2023

Aug 09, 2023

BUY
$4.56 - $9.94 $46,899 - $102,232
10,285 Added 49.5%
31,064 $232,000
Q1 2023

May 08, 2023

BUY
$6.42 - $9.64 $13,135 - $19,723
2,046 Added 10.92%
20,779 $138,000
Q4 2022

Feb 07, 2023

BUY
$7.16 - $12.7 $134,128 - $237,909
18,733 New
18,733 $144,000
Q2 2022

Aug 04, 2022

SELL
$5.04 - $9.26 $82,388 - $151,373
-16,347 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$6.16 - $18.03 $8,562 - $25,061
1,390 Added 9.29%
16,347 $117,000
Q4 2021

Feb 07, 2022

BUY
$16.14 - $21.86 $241,405 - $326,960
14,957 New
14,957 $270,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.24B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.